Literature DB >> 7695636

Potentiation of anti-HIV activity of anti-inflammatory drugs, dexamethasone and indomethacin, by MAP30, the antiviral agent from bitter melon.

A S Bourinbaiar1, S Lee-Huang.   

Abstract

MAP30 is an antiviral protein from bitter melon (Momordica charantia). The enhancement of weak HIV antagonists, dexamethasone and indomethacin, by MAP30 has been examined by measuring the reduction in p24 expression in acutely infected MT-4 lymphocytes. In the presence of 1.5 nM MAP30 the IC50 dose of dexamethasone and indomethacin has been lowered, without concurrent cytotoxicity, at least a thousand-fold to 10(-7) M and 10(-8) M, respectively. This observation indicates that MAP30, a multifunctional antiviral plant protein capable of topological inactivation of viral DNA and specific cleavage of 28 S ribosomal RNA, may regulate HIV replication in concert with steroid and non-steroidal inhibitors of prostaglandin synthesis. The results suggest that use of MAP30 in combination with low pharmacological doses of dexamethasone and indomethacin may improve the efficacy of anti-HIV therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695636     DOI: 10.1006/bbrc.1995.1405

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Cucurbitane-Type Triterpenoids from the Vines of Momordica charantia and Their Anti-inflammatory Activities.

Authors:  Hung-Tse Huang; Li-Jie Zhang; Hui-Chi Huang; Syh-Yuan Hwang; Chia-Lun Wu; Yu-Chi Lin; Chia-Ching Liaw; Yung-Yi Cheng; Susan L Morris-Natschke; Chung-Yi Huang; Kuo-Hsiung Lee; Yao-Haur Kuo
Journal:  J Nat Prod       Date:  2020-05-01       Impact factor: 4.050

Review 2.  Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.

Authors:  Komal Raina; Dileep Kumar; Rajesh Agarwal
Journal:  Semin Cancer Biol       Date:  2016-07-21       Impact factor: 15.707

3.  Antiviral activity of anisomycin against spring viraemia of carp virus in epithelioma papulosum cyprini cells and zebrafish.

Authors:  Yu-Feng Shen; Yang Hu; Bin Zhu; Gao-Xue Wang
Journal:  Virus Res       Date:  2019-05-25       Impact factor: 3.303

Review 4.  Inflammation, HIV, and Immune Quiescence: Leveraging on Immunomodulatory Products to Reduce HIV Susceptibility.

Authors:  Ross Cromarty; Derseree Archary
Journal:  AIDS Res Treat       Date:  2020-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.